The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers.
Daniel Shao-Weng Tan
Research Funding - Novartis
Quan Sing Ng
No relevant relationships to disclose
Dawn Qingqing Chong
No relevant relationships to disclose
Guek Eng Lee
No relevant relationships to disclose
Thuan Tong Tan
No relevant relationships to disclose
Noan Minh Chau
No relevant relationships to disclose
Mei-Kim Ang
No relevant relationships to disclose
Liz Zhong
No relevant relationships to disclose
Balram Chowbay
No relevant relationships to disclose
John Connolly
No relevant relationships to disclose
Eng-Huat Tan
No relevant relationships to disclose
Wan-Teck Lim
No relevant relationships to disclose